title: Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
abstract: We evaluated the efficacy and safety of the combination of docetaxel and cisplatin in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Between June 1999 and December 2002, 50 female MBC patients (median age 43 years; range 29-64) received docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) on day 1 of each 4-week cycle. A total of 226 cycles (median four cycles per patient) were administered as first-line (23 patients) or second-line (27 patients) treatment. Five patients (10%) achieved a complete response (CR) and 15 (30%) had partial responses (PR), giving an overall response rate of 40% (95% CI, 26.4 approximately 53.6%). The median duration of response was 6.1 months (range, 2.3 approximately 29.2(+) months). With a median follow-up of 15.9 months, median time to progression was 6.2 months (range 1 approximately 22.5(+) months). Toxicities included grades III and IV neutropenia in nine (18%) and ten (20%) patients, respectively, and febrile neutropenia in seven patients (14%). In conclusion, our data show that docetaxel plus cisplatin is effective with the manageable toxicity profile in MBC patients previously treated with anthracyclines.
authors.affiliation: Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Poongnap-dong, Songpa-gu, Seoul 138-736, Korea. drjiny@amc.seoul.kr
authors.forename: Jin-Hee
authors.initials: JH
authors.lastname: Ahn
authors.forename: Sung-Bae
authors.initials: SB
authors.lastname: Kim
authors.forename: Hee-Jung
authors.initials: HJ
authors.lastname: Sohn
authors.forename: Jung-Shin
authors.initials: JS
authors.lastname: Lee
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
authors.forename: Woo
authors.initials: W
authors.lastname: Kun Kim
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin